Immunochemical Quantification of Cynomolgus CYP2J2, CYP4A and CYP4F Enzymes in Liver and Small Intestine

Overview

Journal Xenobiotica

Publisher Informa Healthcare

Specialties Biochemistry
Toxicology

Date 2014 Aug 21

PMID 25138712

Citations 2

Authors

Shotaro Uehara

Norie Murayama

Yasuharu Nakanishi

Chika Nakamura

Takanori Hashizume

Darryl C Zeldin

Hiroshi Yamazaki

Yasuhiro Uno

Affiliations

Soon will be listed here.

Abstract

1. An increasing number of studies have indicated the roles of CYP4 proteins in drug metabolism; however, CYP4 expression has not been measured in cynomolgus monkeys, an important animal species for drug metabolism studies. 2. In this study, cynomolgus CYP4A11, CYP4F2/3, CYP4F11 and CYP4F12, along with CYP2J2, were immunoquantified using selective antibodies in 28 livers and 35 small intestines, and their content was compared with CYP1A, CYP2A, CYP2B6, CYP2C9/19, CYP2D, CYP2E1, CYP3A4 and CYP3A5, previously quantified. 3. In livers, CYP2J2, CYP4A11, CYP4F2/3, CYP4F11 and CYP4F12, varied 1.3- to 4.3-fold, represented 11.2, 14.4, 8.0, 2.7 and 0.3% of total immunoquantified CYP1-4 proteins, respectively. 4. In small intestines, CYP2J2, CYP4F2/3, CYP4F11 and CYP4F12, varied 2.4- to 9.7-fold, represented 6.9, 36.4, 2.4 and 9.3% of total immunoquantified CYP1-4 proteins, respectively, making CYP4F the most abundant P450 subfamily in small intestines. CYP4A11 was under the detection limit in all of the samples analyzed. 5. Significant correlations were found in liver for CYP4A11 with lauric acid 11-/12-hydroxylation and for CYP4F2/3 and CYP4F11 with astemizole hydroxylation. 6. This study revealed the relatively abundant contents of cynomolgus CYP2J2, CYP4A11 and CYP4Fs in liver and/or small intestine, suggesting their potential roles for the metabolism of xenobitotics and endogenous substrates.

Citing Articles

Exploring the Interactome of Cytochrome P450 2E1 in Human Liver Microsomes with Chemical Crosslinking Mass Spectrometry.

Davydov D, Dangi B, Yue G, Ahire D, Prasad B, Zgoda V Biomolecules. 2022; 12(2).

PMID: 35204686 PMC: 8869672. DOI: 10.3390/biom12020185.

An update on the role of intestinal cytochrome P450 enzymes in drug disposition.

Xie F, Ding X, Zhang Q Acta Pharm Sin B. 2016; 6(5):374-383.

PMID: 27709006 PMC: 5045550. DOI: 10.1016/j.apsb.2016.07.012.

References

Uno Y, Matsuno K, Nakamura C, Utoh M, Yamazaki H . Cynomolgus macaque CYP4 isoforms are functional, metabolizing arachidonic acid. J Vet Med Sci. 2010; 73(4):487-90. DOI: 10.1292/jvms.10-0333. View

Matsumoto S, Hirama T, Matsubara T, Nagata K, Yamazoe Y . Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab Dispos. 2002; 30(11):1240-5. DOI: 10.1124/dmd.30.11.1240. View

Liu K, Kim M, Lee D, Yoon Y, Kim M, Shon J . Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos. 2006; 34(11):1793-7. DOI: 10.1124/dmd.106.010488. View

Perrett H, Barter Z, Jones B, Yamazaki H, Tucker G, Rostami-Hodjegan A . Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes. Drug Metab Dispos. 2007; 35(10):1733-6. DOI: 10.1124/dmd.107.015743. View

Omura T, Sato R . THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. J Biol Chem. 1964; 239:2370-8. View

Uno Y, Matsushita A, Osada N, Uehara S, Kohara S, Nagata R . Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques. Drug Metab Dispos. 2009; 38(2):209-14. DOI: 10.1124/dmd.109.029710. View

Jin Y, Zollinger M, Borell H, Zimmerlin A, Patten C . CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Dispos. 2010; 39(2):191-8. DOI: 10.1124/dmd.110.035378. View

Wu S, Moomaw C, Tomer K, Falck J, Zeldin D . Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem. 1996; 271(7):3460-8. DOI: 10.1074/jbc.271.7.3460. View

Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich F . Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994; 270(1):414-23. View

10.

Michaels S, Wang M . The revised human liver cytochrome P450 "Pie": absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics. Drug Metab Dispos. 2014; 42(8):1241-51. PMC: 4109210. DOI: 10.1124/dmd.114.058040. View

11.

Uehara S, Murayama N, Nakanishi Y, Nakamura C, Hashizume T, Zeldin D . Immunochemical detection of cytochrome P450 enzymes in small intestine microsomes of male and female untreated juvenile cynomolgus monkeys. Xenobiotica. 2014; 44(9):769-74. PMC: 5515369. DOI: 10.3109/00498254.2014.895882. View

12.

Hashizume T, Mise M, Matsumoto S, Terauchi Y, Fujii T, Imaoka S . A novel cytochrome P450 enzyme responsible for the metabolism of ebastine in monkey small intestine. Drug Metab Dispos. 2001; 29(6):798-805. View

13.

Hsu M, Savas U, Griffin K, Johnson E . Human cytochrome p450 family 4 enzymes: function, genetic variation and regulation. Drug Metab Rev. 2007; 39(2-3):515-38. DOI: 10.1080/03602530701468573. View

14.

King L, Ma J, Srettabunjong S, Graves J, Bradbury J, Li L . Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol. 2002; 61(4):840-52. DOI: 10.1124/mol.61.4.840. View

15.

Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N . A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009; 5(3):e1000433. PMC: 2652833. DOI: 10.1371/journal.pgen.1000433. View

16.

Wang M, Wu J, Bridges A, Zeldin D, Kornbluth S, Tidwell R . Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab Dispos. 2007; 35(11):2067-75. PMC: 2364724. DOI: 10.1124/dmd.107.016428. View

17.

Danese E, Montagnana M, Johnson J, Rettie A, Zambon C, Lubitz S . Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clin Pharmacol Ther. 2012; 92(6):746-56. PMC: 3731755. DOI: 10.1038/clpt.2012.184. View

18.

Uno Y, Hosaka S, Matsuno K, Nakamura C, Kito G, Kamataki T . Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism?. Arch Biochem Biophys. 2007; 466(1):98-105. DOI: 10.1016/j.abb.2007.07.003. View

19.

Nelson D, Zeldin D, Hoffman S, Maltais L, Wain H, Nebert D . Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics. 2004; 14(1):1-18. DOI: 10.1097/00008571-200401000-00001. View

20.

Yamazaki H, Okayama A, Imai N, Guengerich F, Shimizu M . Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. Xenobiotica. 2006; 36(12):1201-9. DOI: 10.1080/00498250600944318. View